In addition to being a sedative, valnoctamide has been investigated for use inepilepsy.[4][5][6]
It was studied forneuropathic pain in 2005 by Winkler et al., with good results: it had minimal effects onmotor coordination and alertness at effective doses, and appeared to be equally effective asgabapentin.[7]
RH Belmaker, Yuly Bersudsky and Alex Mishory started a clinical trial of valnoctamide forprophylaxis ofmania in lieu of the much more teratogenic valproic acid or its salts.[8]
Valnoctamide is aracemic compound with fourstereoisomers,[10] all of which were shown to be more effective than valproic acid in animal models of epilepsy and one of which [(2S,3S]-valnoctamide) was considered to be a good candidate by Isoherranen, et al. for an anticonvulsant in August 2003.[11]
^"valnoctamide - Compound Summary".PubChem Compound. USA: National Center for Biotechnology Information. 26 March 2005. Identification and Related Records. Retrieved20 February 2012.
^Harl, F. M. (March 1964). "[Clinical Study Of Valnoctamide On 70 Neuropsychiatric Clinic Patients Undergoing Ambulatory Treatment]".La Presse Médicale (in French).72:753–754.PMID14119722.
^Haj-Yehia, Abdullah; Meir Bialer (August 1989). "Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity".Pharmaceutical Research.6 (8):683–689.doi:10.1023/A:1015934321764.PMID2510141.S2CID21531402.
^Mattos Nda, S. (May 1969). "[Use of Valnoctamide (nirvanil) in oligophrenic erethics and epileptics]".Hospital (Rio J) (in Portuguese).75 (5):1701–1704.PMID5306499.
^Lindekens, H.; Ilse Smolders; Ghous M. Khan; Meir Bialer; Guy Ebinger; Yvette Michotte (November 2000). "In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy".Pharmaceutical Research.17 (11):1408–1413.doi:10.1023/A:1007559208599.PMID11205735.S2CID24229165.
^RH Belmaker; Yuly Bersudsky; Alex Mishory; Beersheva Mental Health Center (2005)."Valnoctamide in Mania".ClinicalTrials.gov. United States National Institutes of Health. Retrieved25 February 2006.
^Isoherranen, Nina; H. Steve White; Brian D. Klein; Michael Roeder; José H. Woodhead; Volker Schurig; Boris Yagen; Meir Bialer (August 2003). "Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy".Pharmaceutical Research.20 (8):1293–1301.doi:10.1023/A:1025069519218.PMID12948028.S2CID20755032.
^Freifelder, Morris; Geiszler, Adolph O.; Stone, George R. (1961). "Hydrolysis of 5,5-Disubstituted Barbituric Acids".The Journal of Organic Chemistry.26 (1):203–206.doi:10.1021/jo01060a048.ISSN0022-3263.
